Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy

Annals of Oncology

Volumn 18, Issue 9, 2007, Pages 1457-1466

  Cornelio, D B ^a   Roesler, R ^a   Schwartsmann, G ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Bombesin like peptides; Gastrin releasing peptide receptor; Ggastrin releasing peptide

Indexed keywords

2 PYRROLINODOXORUBICIN; AMBAMUSTINE LU 177; AN 215; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BOMBESIN; BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; CAMPTOTHECIN; CETRORELIX; CISPLATIN; DEMOBESIN TC 99M; ETOPOSIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONIST; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2A11; MONOCLONAL ANTIBODY 2A11 IN 111; OCTREOTIDE Y 90; OKT 3; PACLITAXEL; PENTADECAPEPTIDE TC 99M; PENTETREOTIDE; PEPTIDE HORMONE ANTAGONIST; RADIOPHARMACEUTICAL AGENT; RC 3094; RC 3095; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

ANTISENSE THERAPY; BINDING AFFINITY; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CARCINOMA IN SITU; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG CONJUGATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; ESOPHAGUS CARCINOMA; GASTRINOMA; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; INJECTION SITE DISCOMFORT; ISOTOPE LABELING; KIDNEY CANCER; LEIOMYOMA; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOACTIVITY; RECOMMENDED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; BOMBESIN; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASMS; RECEPTORS, BOMBESIN; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548459014     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm058     Document Type: Review

References (127)

1. Perona R. Cell signaling: Growth factors and tyrosine kinase receptors. Clin Transl Oncol 2006; 8 (2): 77-82.
2. Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol 2005; 32 (6 Suppl 10): S23-S29.
3. Nathan P, Chao D, Brock C et al. The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer 2006; 94 (9): 1217-1220.
4. Rajpal S, Venuk AP. Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol 2006; 4 (2): 124-132.
5. Cuttitta F, Carney DN, Mulshine J et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823-826.
6. Chu KU, Evers BM, Ishizuka J et al. Role of bombesin on gut mucosal growth. Ann Surg 1995; 222: 94-100.
7. Narayan S, Guo YS, Towsend CM Jr et al. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro. Cancer Res 1990; 50: 6772-6778.
8. Stangelberger A, Schally AV, Varga JL et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 2005; 11 (1): 49-57.
9. Kahan Z, Sun B, Schally AV et al. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/ gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. Cancer 2000; 88 (6): 1384-1392.
10. Bajo AM, Schally AV, Groot K, Szepeshazi K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004; 90 (1): 245-252.
11. Plonowski A, Schally AV, Varga JL et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 2000; 44 (2): 172-180.
12. Szepeshazi K, Halmos G, Schally AV et al. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 1999; 125 (8-9): 444-452.
13. Schwartsmann G, DiLeone LP, Horowitz M et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24 (5): 403-412.
14. Anastasi A, Erspamer V, Bucci M. Isolation and structure at bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombesina and Alytes. Experientia 1971; 27: 166-169.
15. Johnson DE, Lock JE, Elde RP, Thompson TR. Pulmonary neuroendocrine cells in hyaline membrane disease and bronchopulmonary dysplasia. Pediatr Res 1982; 16: 446-454.
16. Sunday ME, Kaplan LM, Motoyama E et al. Biology of disease: gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 1988; 59: 5-24.
17. Battey J, Wada E. Two distinct receptors subtypes for mammalian bombesin-like peptides. Trends Neurosci 1991; 14: 524-528.
18. Minna J. Bombesin receptor gene cloned. Science 1990; 249: 1377.
19. Battey JF, Way JM, Corjay MH et al. Molecular cloning of the bombesin/ gastrin releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA 1991; 88: 395-399.
20. Spindel ER, Giladi E, Brehm P et al. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin releasing peptide receptor. Mol Endocrinol 1990; 4: 1956-1963.
21. Wada E, Way J, Shapira H et al. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron 1991; 6: 421-430.
22. Fathi Z, Corjay MH, Shapira H et al. BRS-3: A novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993; 268: 5979-5984.
23. Iacangelo A, Affolter HU, Eiden LE et al. Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. Nature 1986; 232: 82-86.
24. Helmich MR, Ives KL, Udupi V et al. Multiple protein kinase pathways are involved in gastrin-releasing peptide receptor-regulated secretion. J Biol Chem 1999; 274: 23901-23909.
25. Aprikian AG, Tremblay L, Han K, Chevalier S. Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorilation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997; 72: 498-504.
26. Bunnett N. Gastrin releasing peptide. In: Walsh JH, Dockray GJ (eds): Gut Peptides: Biochemistry and Physiology. New York, NY: Raven Press 1994; 423-445.
27. Roesler R, Luft T, Oliveira SH et al. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology 2006; 51 (2): 350-357.
28. Roesler R, Henriques JA, Schwartsmann G. Gastrin-releasing Peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 2006; 5 (2): 197-204.
29. Dantas AD, Luft T, Henriques JA et al. Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: Possible involvement of the GABAergic system. Peptides 2006;27 (9): 2307-2312.
30. Martins MR, Reinke A, Valvassori SS et al. Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. Peptides 2005; 26 (12): 2525-2529.
31. Venturella R, Lessa D, Luft T et al. Dexamethasone reverses the memory impairment induced by antagonism of hippocampal gastrin-releasing peptide receptors. Peptides 2005; 26 (5): 821-825.
32. Meller CA, Henriques JA, Schwartsmann G et al. The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice. Peptides 2004; 25 (4): 585-588.
33. Roesler R, Henriques JA, Schwartsmann G. Neuropeptides and anxiety disorders: Bombesin receptors as novel therapeutic targets. Trends Pharmacol Set 2004; 25 (5): 241-242; author reply 242-243.
34. Roesler R, Lessa D, Venturella R et al. Bombesin/gastrin-releasing peptide receptors in the basolateral amygdala regulate memory consolidation. Eur J Neurosci 2004;19 (4): 1041-1045.
35. Roesler R, Kopschina MI, Rosa RM et al. RC-3095, a bombesin/ gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol 2004; 486 (1): 35-41.
36. Roesler R, Meller CA, Kopschina MI et al. Intrahippocampal infusion of the bombesin/gastrin-releasing peptide antagonist RC-3095 impairs inhibitory avoidance retention. Peptides 2003; 24 (7): 1069-1074.
37. Dal Pizzol F, Di Leone LP, Ritter C et al. Gastrin-releasing peptide receptor antagonist effects on an animal model of sepsis. Am J Respir Crit Care Med 2006; 173 (1): 84-90.
38. Rozengurt E, Sinneth-Smith J. Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci USA 1983; 80: 2936-2940.
39. Willey JC, Lechner JF, Harris CC. Bombesin and the C-terminal tetradecapeptide at gastrin releasing peptide are growth factors for normal human bronchial epithelial cells. Exp Cell Res 1984; 153: 245-248.
40. +2 efflux in human breast cancer cells by bombesin. Cancer Res 1990; 50: 235-239.
41. Parekh D, Ishizuka J, Towsend CM Jr et al. Characterization of a human pancreatic carcinoid in vitro: Morphology, amine and peptide storage, and secretion. Pancreas 1994; 9: 83-90.
42. Alexander RW, Upp JR Jr, Poston GJ et al. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res 1988; 48: 1439-1441.
43. Bold RJ, Kim HJ, Ishizuka J et al. A human gastric cell line possesses a functional receptor for gastrin-releasing peptide. Cancer Invest 1998; 16: 12-17.
44. Kim HJ, Evers BM, Guo Y et al. Bombesin-mediated AP-1 activation in a human gastric cancer (SIIA). Surgery 1996; 120: 130-136.
45. Burns DM, Walker B, Gray J, Nelson J. Breast cancer cell-associated endopeptidade EC 24.11 modulates proliferative responses to bombesin. Br J Cancer 1999; 79: 214-220.
46. Bologna M, Festuccia C, Muzi P et al. Bombesin stimulates growth at human prostatic cancer cells in vitro. Cancer 1989; 63: 1714-1720.
47. Logothetis C, Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J Cell Biochem Suppl 1992; 16H: 128-134.
48. Bartholdi MF, Wu JM, Pu H, Troncoso P. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer 1998; 79 (1): 82-90.
49. Markwalder R, Reubi JC. Gastrin-releasing Peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159.
50. Sun B, Halmos G, Schally AV et al. Presence of receptors for bombesin/ gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000; 42 (4): 295-303.
51. Reubi JC, Wenger S, Schmuckli-Maurer J et al. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002; 8 (4):1139-1146.
52. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/ gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995; 55 (2): 280-287.
53. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999; 155 (6): 2067-2076.
54. Sun B, Schally AV, Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 2000; 90 (1-3): 77-84.
55. Ehlers RA, Kim S, Zhang Y et al. Gut Peptide receptor expression in human pancreatic cancers. Ann Surg 2000; 231 (6): 838-848.
56. Tang C, Biemond I, Offerhaus GJ et al. Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumor-free pancreas. Br J Cancer 1997; 75 (10): 1467-1473.
57. Fleischmann A, Laderach U, Friess H et al. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000; 80 (12): 1807-1817.
58. Preston SR, Woodhouse LF, Jones-Blackett S et al. High affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br J Cancer 1995; 71 (5): 1087-1089.
59. Chave HS, Gough AC, Palmer K et al. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 2000; 82 (1): 124-130.
60. Saurin JC, Roualt JP, Abello J et al. High gastrin-releasing peptide receptor mRNA level is related to tumor dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur J Cancer 1999; 35 (1): 125-132.
61. Carroll RE, Matkowskyj KA, Ghakrabarti S et al. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 1999; 276 (3 Pt 1): G655-G665.
62. Pansky A, De Weerth A, Fasler-Kan E et al. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. J Am Soc Nephrol 2000; 11 (8): 1409-1418.
63. Heuser M, Schlott T, Schally AV et al. Expression of gastrin releasing peptide receptor in renal cell carcinomas: A potential function for the regulation of neoangiogenesis and microvascular perfusion. J Urol 2005; 173: 2154-2159.
64. Uchida K, Kojima A, Morokawa N et al. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol 2002; 128 (12): 633-640.
65. Lango MN, Dyer KF, Lui VW at al. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Nat Cancer Inst 2002; 94 (5): 375-383.
66. Kim S, Hu W, Kelly DR et al. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg 2002; 235 (5): 621-629.
67. Sebesta JA, Young A, Bullock J et al. Gastrin-releasing peptide: A potential growth factor expressed in human neuroblastoma tumors. Curr Surg 2001; 58 (1): 86-89.
68. Fang MZ, Liu C, Song Y et al. Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas. Carcinogenesis 2004; 25 (6): 865-871.
69. Scott N, Millward E, Cartwright EJ et al. Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. J Clin Pathol 2004; 57 (2): 189-192.
70. Preston SR, Woodhouse LF, Jones-Blackett S et al. High affinity binding sites for gastrin releasing peptide on human gastric cancer and Menetrier's mucosa. Cancer Res 1993; 53 (21): 5090-5092.
71. Carroll RE, Carroll R, Benya RV. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas. Peptides 1999; 20 (2): 229-237.
72. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin - active or bystander in gastric carcinogenesis? Nat Rev Cancer 2006; 6 (12): 936-946.
73. Fleischmann A, Waser B, Gebbers JO, Reubi JC. Gashin-releasing peptide receptors in normal and neoplastic human uterus: Involvement of multiple tissue compartments. J Clin Endocrinol Metab 2005; 90 (8): 4722-4729.
74. 3]-Octreotide: The Rotterdam experience with more than 1000 patents. Eur J Nucl Med 1993; 20: 716-731.
75. Saga T, Tamaki N, Itoi K et al. Phase III additional clinical study of 111Inpentetreotide (MP-1727): Diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors. Kaku Igaku 2003; 40 (2): 185-203.
76. Waldherr C, Pless Maecke HR et al. The clinical value of [90Y-DOTA]-DPhe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study. Ann Oncol 2001; 12: 941-945.
77. Baidoo KE, Lin K-S, Zhan Y et al. Design, synthesis, and initial evaluation of high affinity technetium bombesin analogues. Bioconjug Chem 1998; 9: 218-225.
78. Varvarigou A, Bouziotis P, Zikos C et al. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm 2004; 19 (2): 219-229.
79. De Vicentis G, Scopinaro F, Varvarigou A et al. Phase I Mal of technetium [Leu13] bombesin as cancer seeking agent: Possible scintigraphic guide for surgery? Tumori 2002; 88 (3): S28-S30.
80. Nock B, Nikolopoulou A, Chiotellis E et al. Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumor imaging. Eur J Nucl Med 2003; 30 (2): 247-258.
81. Lantry LE, Capeleth E, Maddalena ME et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47 (7): 1144-1152.
82. Casibang M, Moody TW. (Tyr(0),Bpa(4))bombesin is a GRP receptor agonist. Peptides 2000; 21 (5): 649-653.
83. Darker JG, Brough SJ, Heath J, Smart D. Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2). J Pept Sci 2001; 7 (11): 598-605.
84. Van de Wiele C, Dumont F, Dierckx RA et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 2001; 42 (11): 1722-1727.
85. Breeman WA, De Jong M, Bernard BF et al. Pre-clinical evaluation of [(111)IQDTPA-Pro(1), Tyr(4)lbombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999; 83 (5): 657-663.
86. Smith CJ, Volkert WA, Hoffmann TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 2005; 32 (7): 733-740.
87. Scopinari F, De Vicentis G, Vantarigou AD. Use of radiolabeled bombesin in humans. J Clin Oncol 2005; 23 (13): 3170-3171.
88. Chaudhry A, Carrasquillo JA, Avis IL et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients lung cancer. Clin Cancer Res 1999; 5 (11): 3385-3393.
89. Kelley MJ, Linnoila RI, Avis IL et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997; 112 (1): 256-261.
90. Zhou J, Chen Z, Zhong R et al. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res 2006; 12 (7 Pt 1): 2224-2231.
91. Chen J, Mokotoff M, Zhou JH et al. An immunoconjugate of Lys3-bombesin and monoclonal antibody-22 can specifically induce FcgammaRI (CD64)-dependent monocyte- and neutrophil-mediated lysis of small cell carcinoma of the lung cells. Clin Cancer Res 1995; 1 (4): 425-434.
92. Zhou J, Chen Z, Mokotoff J. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res 2003; 9 (13): 4953-4960.
93. Buchholz S, Keller G, Schally AV et al. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA 2006; 103 (27): 10403-10407.
94. Engel JB, Schally AV, Halmos G et al. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocrin Relat Cancer 2005; 12 (4): 999-1009.
95. Keller G, Schally AV, Nagy A et al. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. Cancer 2005; 104 (10): 2266-2274.
96. Szepeshazi A, Schally AV, Nagy A, Halmos G. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas 2005; 31 (3): 275-282.
97. Engel JB, Schally AV, Halmos G et al. Experimental therapy of human endometrial cancers with a targeted cytotaxic bombesin analog AN-215: low induction of multidrug resistance proteins. Eur J Cancer 2005; 41 (12): 1824-1830.
98. Stangelberger A, Schally AV, Letsh M et al. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer 2006; 118 (1): 222-229.
99. Kanashiro GA, Schally AV, Nagy A, Halmos G. Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic ana antiapoptotic mechanisms. Int J Oncol 2005; 27 (1): 169-174.
100. Safavy A, Bonner JA, Waksal HW et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 2003; 14 (2): 302-310.
101. Safavy A, Ralsch KP, Matusiak D et al. Single-drug multiligand conjugates: Synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide "scorpion" molecule. Bioconjug Chem 2006; 17 (3): 565-570.
102. Moody TW, Sun LC, Mantey SA et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther 2006; 318 (3): 1265-1272.
103. Jungwirth A, Galvan G, Pinski J et al. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice, Prostate 1997; 32 (3): 164-172.
104. Miyazaki M, Lamharzi N, Schally AV et al. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/ gastrin-releasing peptide (GRP) antagonists RC-3940-II and IRC-3095. Eur J Cancer 1998; 34 (5): 710-717.
105. Baja AM, Schally AV, Krupa M et al. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci USA 2002; 99 (6): 3836-3841.
106. Szepeshazi K, Schally AV, Halmos G et al. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc Natl Acad Sci USA 1997; 94 (20): 10913-10918.
107. Koppan M, Halmos G, Arencibia JM et al. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 1996, 83 (7): 1335-1343.
108. Kiaris H, Schally AV, Sun B et al. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/ gastrin-releasing peptide. Oncogene 1999; 18 (50): 7168-7173.
109. Chatzistamou I, Schally AV, Sun B et al. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c-jun and c-fos oncogene expression by bombesin antagonists. Br J Cancer 2000; 83 (7): 906-913.
110. Moody TW, Venugopal R, Zia F et al. BW2258U89: A GRP receptor antagonist which inhibits small cell lung cancer growth. Life Sci 1995; 56 (7): 521-529.
111. Marquez C, Treston A, Moody E et al. The metabolism of BW2258U89, a GRP receptor antagonist. Neuropeptides 2000; 34 (2): 108-115.
112. Moody TW, Venugopal R, Hu V et al. BW 1023U90: A new GRP receptor antagonist for small-cell lung cancer cells. Peptides 1996; 17 (8):1337-1343.
113. Moody TH, Leyton J, Garcia-Marin, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol 2003; 474: 21-29.
114. Ashwood V, Brownhill V, Higginbottom M et al, PD 176252 - the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett 1998; 8 (18): 2589-2594.
115. Tokita K, Katsuno T, Hocart SJ et al, Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem 2001; 276 (39): 36652-36663.
116. Azay J, Gagne D, Devin C et al. JMV641: A patent bombesin receptor antagonist that inhibits Swiss 3T3 cell proliferation. Regul Pept 1996; 65 (1): 91-97.
117. Mihara S, Hara M, Nakamura M et al. Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun 1995; 213 (2): 594-599.
118. Wada M, Doi R, Hosotani R et al. Effect of a new bombesin receptor antagonist, (E)-alkene bombesin isostere, on amylase release from rat pancreatic acini. Pancreas 1995; 10 (3): 801-305.
119. Llinares M, Devin C, Chaloin O et al. Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res 1999; 53 (3): 275-283.
120. Degen LP, Peng F, Collet A et al. Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Gastroenterology 2001; 120 (2): 361-368.
121. Lehmann F, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs 2003; 63: 1785-1797.
122. Kim R, Emi M, Matsuura K, Tanabe K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 2007; 14 (1): 1-11.
123. Langer DA, Kautzman D, Kane MA. Inhibition of proliferation of human small cell lung cancer cells expressing an autocrine system for gastrin releasing peptide by antisense oligodeoxynucleotides to gastrin releasing peptide receptor. Lung Cancer 2002; 36 (3): 235-242.
124. Oremek GM, Sapoutzis N. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer. Anticancer Res 2003; 23 (2A): 895-898.
125. Yonemori K, Sumi M, Fujimoto N et al. Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation. Cancer 2005; 104 (4): 811-816.
126. Nisman B, Heching N, Biran H et al. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol 2006; 27 (1): 8-16.
127. Yashi M, Nukui A, Kurokawa S et al. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 2003; 56 (4): 305-312.